Science Explorer Back to mapMap

Most cited papers from Sage Therapeutics (United States)

What are the most cited papers from Sage Therapeutics (United States)?

The most cited paper from Sage Therapeutics (United States) is "Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1" (Daniel J. Klionsky et al., 2021), with 2,743 citations. Next come "Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials" (800) and "Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia" (496).

Showing 50 of 60 papers. Every paper with more than 49 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1 Daniel J. Klionsky et al. · Autophagy Open access2,930 authors 2 Jan 2021 2,743
2 Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials Samantha E Meltzer-Brody, Helen Colquhoun, Robert A. Riesenberg et al. · The Lancet 31 Aug 2018 800
3 Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia Adriana E. Tron et al. · Nature Communications Open access 11 Dec 2018 496
4 Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial Stephen Kanes, Helen Colquhoun, Handan Gunduz‐Bruce et al. · The Lancet 13 Jun 2017 484
5 Efficacy and Safety of Lisdexamfetamine for Treatment of Adults With Moderate to Severe Binge-Eating Disorder Susan L. McElroy, James I. Hudson, James Earl Mitchell et al. · JAMA Psychiatry 14 Jan 2015 321
6 Impact of Cross-Coupling Reactions in Drug Discovery and Development Melissa J. Buskes, Marı́a-Jesús Blanco · Molecules Open access 31 Jul 2020 305
7 Effect of Zuranolone vs Placebo in Postpartum Depression Kristina M. Deligiannidis, Samantha E Meltzer-Brody, Handan Gunduz‐Bruce et al. · JAMA Psychiatry Open access 30 Jun 2021 274
8 The Major Brain Cholesterol Metabolite 24(S)-Hydroxycholesterol Is a Potent Allosteric Modulator ofN-Methyl-d-Aspartate Receptors Steven M. Paul, James Doherty, Albert J. Robichaud et al. · Journal of Neuroscience Open access 30 Oct 2013 269
9 Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial Ingo K. Mellinghoff, Min Lu, Patrick Yung Wen et al. · Nature Medicine Open access 23 Feb 2023 241
10 Trial of SAGE-217 in Patients with Major Depressive Disorder Handan Gunduz-Bruce, Christopher Silber, Inder Kaul et al. · New England Journal of Medicine 4 Sep 2019 234
11 The Economic Burden of Adults with Major Depressive Disorder in the United States (2019) Paul E. Greenberg, A.S. Chitnis, Derek J. Louie et al. · Advances in Therapy Open access 30 Jul 2023 221
12 Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2 Michael P. Clark et al. · Journal of Medicinal Chemistry Open access 14 Jul 2014 219
13 Lipophilic Permeability Efficiency Reconciles the Opposing Roles of Lipophilicity in Membrane Permeability and Aqueous Solubility Matthew R. Naylor, Andrew M. Ly, Mason J. Handford et al. · Journal of Medicinal Chemistry 5 Nov 2018 207
14 Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo Janeta V. Popovici-Müller, Jeffrey O. Saunders, Francesco G. Salituro et al. · ACS Medicinal Chemistry Letters Open access 17 Sep 2012 201
15 Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression Miranda Cooper, H. Kilvert, Paul Hodgkins et al. · CNS Drugs Open access Oct 2019 192
16 Costs, length of stay, and mortality of super‐refractory status epilepticus: A population‐based study from Germany Adam Strzelczyk, Sonja Ansorge, Jana Hapfelmeier et al. · Epilepsia 6 Jul 2017 192
17 Cyclic peptide natural products chart the frontier of oral bioavailability in the pursuit of undruggable targets Matthew R. Naylor, Andrew T. Bockus, Marı́a-Jesús Blanco et al. · Current Opinion in Chemical Biology Review 30 May 2017 189
18 Mean arterial pressure and mortality in patients with distributive shock: a retrospective analysis of the MIMIC-III database Jean‐Louis Vincent, Nathan D. Nielsen, Nathan Ivan Shapiro et al. · Annals of Intensive Care Open access 2018 185
19 The 2016 ACR Commission on Human Resources Workforce Survey Edward I. Bluth, Swati Bansal · Journal of the American College of Radiology 4 Aug 2016 173
20 Neuroactive steroids for the treatment of status epilepticus Michael A. Rogawski, Carlos M. Loya, Kiran Reddy et al. · Epilepsia Open access Sep 2013 161
21 Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression Stephen Kanes, Helen Colquhoun, James Doherty et al. · Human Psychopharmacology Clinical and Experimental Open access Mar 2017 151
22 Impact of Major Depressive Disorder on Comorbidities Alix M. Arnaud, Teri S. Brister, Ken Duckworth et al. · The Journal of Clinical Psychiatry Open access 18 Oct 2022 149
23 Allopregnanolone in postpartum depression: Role in pathophysiology and treatment Samantha E Meltzer-Brody, Stephen Kanes · Neurobiology of Stress Open access 3 Feb 2020 134
24 Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator Alison L. Althaus, Michael A. Ackley, Gabriel M. Belfort et al. · Neuropharmacology Open access 22 Sep 2020 132
25 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner Man Ying Wong, Michael Lewis, James Doherty et al. · Journal of Neuroinflammation Open access 17 Jun 2020 124
26 Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1 H -pyrazol-1′-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid) A Receptor Gabriel Martinez Botella, Francesco G. Salituro, Boyd L. Harrison et al. · Journal of Medicinal Chemistry Open access 28 Jul 2017 123
27 Pediatric super‐refractory status epilepticus treated with allopregnanolone Eileen M. Broomall, JoAnne E. Natale, Michele Grimason et al. · Annals of Neurology Open access Nov 2014 120
28 Allopregnanolone Mediates Affective Switching Through Modulation of Oscillatory States in the Basolateral Amygdala Pantelis Antonoudiou, Phillip L.W. Colmers, Najah L. Walton et al. · Biological Psychiatry Open access 27 Jul 2021 119
29 Safety and target engagement of an oral small-molecule sequestrant in adolescents with autism spectrum disorder: an open-label phase 1b/2a trial A. Stewart Campbell, Brittany D. Needham, Christopher R. Meyer et al. · Nature Medicine Open access 14 Feb 2022 108
30 Brexanolone as adjunctive therapy in super‐refractory status epilepticus Eric S. Rosenthal, Jan Claassen, Mark S. Wainwright et al. · Annals of Neurology Open access 5 Aug 2017 100
31 Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study Jamie Adams et al. · npj Parkinson s Disease Open access 17 Apr 2023 98
32 Blocking extracellular activation of myostatin as a strategy for treating muscle wasting Michelle Pirruccello, Justin Jackson, Stefan Wawersik et al. · Scientific Reports Open access 29 Jan 2018 94
33 AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study Robert E. Litman, Mark A. Smith, James Doherty et al. · Schizophrenia Research 26 Feb 2016 87
34 Different oxysterols have opposing actions at N-methyl-d-aspartate receptors Andrew J. Linsenbardt, Amanda Taylor, Christine M. Emnett et al. · Neuropharmacology Open access 27 May 2014 87
35 Allosteric modulation of NMDA receptors prevents the antibody effects of patients with anti-NMDAR encephalitis Francesco Mannara, Marija Radosevic, Jesús Planagumà et al. · Brain Open access 11 Jun 2020 84
36 Burden and epidemiology of status epilepticus in infants, children, and adolescents: A population‐based study on German health insurance data Susanne Schubert‐Bast, Johann Philipp Zöllner, Sonja Ansorge et al. · Epilepsia 13 Apr 2019 78
37 Endogenous and synthetic neuroactive steroids evoke sustained increases in the efficacy of GABAergic inhibition via a protein kinase C-dependent mechanism Amit Modgil, Manasa L. Parakala, Michael A. Ackley et al. · Neuropharmacology Open access 16 Oct 2016 77
38 Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program Cynthia Neill Epperson, David R. Rubinow, Samantha E Meltzer-Brody et al. · Journal of Affective Disorders Open access 30 Sep 2022 76
39 A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression Erica M. Richards, Daniel C. Mathews, David A. Luckenbaugh et al. · Psychopharmacology Open access 4 Jan 2016 76
40 Impact of Allosteric Modulation in Drug Discovery: Innovation in Emerging Chemical Modalities Bingsong Han, Francesco G. Salituro, Marı́a-Jesús Blanco · ACS Medicinal Chemistry Letters Open access 10 Mar 2020 73
41 2018 ACR Commission on Human Resources Workforce Survey Claire E. Bender, Swati Bansal, Darcy J. Wolfman et al. · Journal of the American College of Radiology 10 Feb 2019 70
42 Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis Geneviève Gauthier, Annie Guérin, Maryia Zhdanava et al. · BMC Psychiatry Open access 19 Jun 2017 70
43 Zuranolone in Major Depressive Disorder Anita H. Clayton, Robert A. Lasser, Indrani M. Nandy et al. · The Journal of Clinical Psychiatry Open access 17 Feb 2023 69
44 Towards Resolving the Pro- and Anti-Tumor Effects of the Aryl Hydrocarbon Receptor Supraja Narasimhan, Elizabeth Zulick, Olga Novikov et al. · International Journal of Molecular Sciences Open access 7 May 2018 66
45 Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas Raphael Koch, Amanda L. Christie, Jennifer Leigh Crombie et al. · Blood Open access 30 Nov 2018 65
46 A Novel, Synthetic, Neuroactive Steroid Is Effective at Decreasing Depression-Like Behaviors and Improving Maternal Care in Preclinical Models of Postpartum Depression Laverne Camille Melón, Rebecca Hammond, Michael Lewis et al. · Frontiers in Endocrinology Open access 23 Nov 2018 63
47 Essential tremor patients experience significant burden beyond tremor: A systematic literature review Margaret E. Gerbasi, Shruti Nambiar, Spencer Reed et al. · Frontiers in Neurology ReviewOpen access 22 Jul 2022 62
48 VX-509 (Decernotinib) Is a Potent and Selective Janus Kinase 3 Inhibitor That Attenuates Inflammation in Animal Models of Autoimmune Disease Sudipta Mahajan, James K. Hogan, Dina Shlyakhter et al. · Journal of Pharmacology and Experimental Therapeutics 12 Mar 2015 62
49 SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies Ethan C. Hoffmann, George G. Nomikos, Inder Kaul et al. · Clinical Pharmacokinetics Open access 24 Jul 2019 59
50 The future of fungi: threats and opportunities Nicola T. Case et al. · G3 Genes Genomes Genetics Open access 30 Sep 2022 57

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.